Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 ...

Eli Lilly has arguably taken the lead in the obesity drug space. Novo Nordisk has struggled, but remains a top contender with ...

Danish drugmaker Novo Nordisk (NVO) slipped 6% in early trading on Friday after U.S. President Donald Trump said on Thursday ...

Novo Nordisk A/S and Eli Lilly & Co. shares fell after President Donald Trump said the price of the blockbuster diabetes drug ...

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-loss ...

During a press conference, Trump specifically mentioned Ozempic, referring to it as "the fat loss drug" when asked about a $1 ...

Hims & Hers is emerging as a disruptive force in the obesity treatment market, challenging established GLP-1 drug makers.

NEW YORK >> WeightWatchers said on Monday it will partner with Amazon to deliver medications including injectable GLP-1 ...

Novo Nordisk and Eli Lilly stocks fell after Trump announced Ozempic prices could drop to $150 monthly from $1,000.